Global Information
회사소개 | 문의 | 위시리스트

카텝신 K : 파이프라인 리뷰

Cathepsin K - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 08월 상품 코드 365732
페이지 정보 영문 40 Pages
가격
US $ 3,500 ₩ 4,118,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,237,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 12,356,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


카텝신 K : 파이프라인 리뷰 Cathepsin K - Pipeline Review, H2 2019
발행일 : 2019년 08월 페이지 정보 : 영문 40 Pages

카텝신 K를 표적으로 한 치료제 개발 파이프라인의 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관에 의해 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트에 관한 정보 등을 최신 뉴스 및 발표와 함께 정리하여 전해드립니다.

서론

  • 조사 범위

카텝신 K 개요

치료제 개발

  • 개발중인 제품 : 개발 단계별
  • 개발중인 제품 : 치료 영역별
  • 개발중인 제품 : 증상별

파이프라인 제품 개요

  • 후기 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

치료제 평가

  • 단일요법/병용 치료제의 경우
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개발에 참여하고 있는 기업

  • Amura Holdings Limited
  • Medivir AB
  • Merck & Co., Inc.
  • Virobay Inc.
  • Wroclawskie Centrum Badan EIT+ Sp. z o.o.

약제 개요

휴지중인 프로젝트

개발이 중지된 제품

주요 뉴스 및 프레스 릴리스

부록

도표

KSA 16.08.22

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Evotec SE, H2 2019
  • Pipeline by Mateon Therapeutics Inc, H2 2019
  • Pipeline by Medivir AB, H2 2019
  • Pipeline by Virobay Inc, H2 2019
  • Pipeline by Wroclawskie Centrum Badan EIT+ Sp z oo, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019

Summary:

According to the recently published report 'Cathepsin K - Pipeline Review, H2 2019'; Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) pipeline Target constitutes close to 5 molecules.

Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Cathepsin K or CTSK is an enzyme encoded by CTSK gene. It is closely involved in osteoclastic bone resorption and participates partially in the disorder of bone remodeling. It plays an important role in extracellular matrix degradation. The enzyme is ability to catabolize elastin, collagen, and gelatin allow it to break down bone and cartilage.

The report 'Cathepsin K - Pipeline Review, H2 2019' outlays comprehensive information on the Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 1 and 3 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Infectious Disease and Musculoskeletal Disorders which include indications Bone Cancer, Chagas Disease (American Trypanosomiasis), Neuropathic Pain (Neuralgia) and Osteoarthritis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38)
  • The report reviews Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Overview
  • Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Companies Involved in Therapeutics Development
    • Evotec SE
    • Mateon Therapeutics Inc
    • Medivir AB
    • Virobay Inc
    • Wroclawskie Centrum Badan EIT+ Sp z oo
  • Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Drug Profiles
    • KGP-207 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MIV-711 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-114137 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CTSK for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VBY-285 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Dormant Products
  • Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Discontinued Products
  • Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Product Development Milestones
    • Featured News & Press Releases
      • May 06, 2019: Safety and efficacy data from the MIV-711 phase II open label extension study presented at the OARSI world congress
      • Apr 30, 2019: Data from the MIV-711 phase II program to be presented at the OARSI World Congress
      • Oct 19, 2018: New data from the MIV-711 phase II program will be presented at the ACR Annual Meeting on October 21
      • Jul 27, 2018: MIV-711 osteoarthritis phase IIa extension study outcomes show continuing positive effect on joint structure
      • Jun 28, 2018: Medivir Announces Positive Top-line Results From the MIV-711 Osteoarthritis Phase IIa Extension Study
      • Apr 26, 2018: Medivir AB: Data From the MIV-711 Initial Phase IIa Study Will be Presented at the OARSI World Congress on April 27
      • Nov 09, 2017: MIV-711 phase IIa osteoarthritis study data presented as a late breaking poster at the Annual Meeting of the American College for Rheumatology
      • Oct 24, 2017: Medivir Receives FDA Fast Track Designation for MIV-711 for the Treatment of OA
      • Oct 20, 2017: MIV-711 phase IIa osteoarthritis study data selected as late breaking abstract at the Annual Meeting of the American College for Rheumatology
      • Sep 25, 2017: Medivir announces Positive Topline Results from phase IIA osteoarthritis study, showing disease-modifying benefit of MIV-711 on joint structure
      • Sep 14, 2017: Data monitoring committee gives "Go Ahead" in the MIV-711 osteoarthritis extension study
      • Aug 16, 2017: FDA accepts Medivir´s IND application for MIV-711, enabling clinical development in the US
      • Jun 09, 2017: Medivir - Enrolment Completed in the MIV-711 Osteoarthritis Extension Study and Data Monitoring Committee Recommendation to "Go Ahead"
      • Feb 01, 2017: MIV-711 Osteoarthritis Trial: Successful fourth independent review of safety data enables trial continuation without any modifications
      • Dec 08, 2016: MIV-711 Osteoarthritis Trial: Successful Third Independent Review of Safety Data and Trial Continues Without any Modifications
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q